Pharmacoeconomic Study on Miglitol and Acarbose in the Treatment of Type 2 Diabetes

ZHUANG Jianrong; ZHENG Peiying; CHEN Huiping; WANG Jiakun; CHEN Zhimin

doi:10.14009/j.issn.1672-2124.2020.04.019

您当前的位置：

首页 >

文章列表页 >

Pharmacoeconomic Study on Miglitol and Acarbose in the Treatment of Type 2 Diabetes

更新时间：2022-10-08

- Pharmacoeconomic Study on Miglitol and Acarbose in the Treatment of Type 2 Diabetes
- Vol. 20, Issue 4, Pages: 453-455(2020)
- 作者机构：
  
  1. 解放军第910医院药学科
  2. 解放军第910医院消毒供应中心
- 作者简介：
- 基金信息：
- DOI：10.14009/j.issn.1672-2124.2020.04.019
  CLC： R587.1
- Published：2020，
扫描看全文
[1]庄建荣,郑培英,陈惠萍,王佳坤,陈志民.米格列醇与阿卡波糖治疗2型糖尿病的药物经济学研究[J].中国医院用药评价与分析,2020,20(04):453-455+462.

ZHUANG Jianrong, ZHENG Peiying, CHEN Huiping, et al. Pharmacoeconomic Study on Miglitol and Acarbose in the Treatment of Type 2 Diabetes. [J]. 20(4):453-455(2020)
[1]庄建荣,郑培英,陈惠萍,王佳坤,陈志民.米格列醇与阿卡波糖治疗2型糖尿病的药物经济学研究[J].中国医院用药评价与分析,2020,20(04):453-455+462. DOI： 10.14009/j.issn.1672-2124.2020.04.019.

ZHUANG Jianrong, ZHENG Peiying, CHEN Huiping, et al. Pharmacoeconomic Study on Miglitol and Acarbose in the Treatment of Type 2 Diabetes. [J]. 20(4):453-455(2020) DOI： 10.14009/j.issn.1672-2124.2020.04.019.

摘要

目的:比较米格列醇与阿卡波糖治疗2型糖尿病的药物经济学效果。方法:将2017年9月至2018年8月解放军第910医院门诊收治的2型糖尿病患者100例按就诊顺序分为两组

单号为米格列醇组

双号为阿卡波糖组

每组50例。米格列醇组患者口服米格列醇片治疗

阿卡波糖组口服阿卡波糖片治疗。两组患者均联合二甲双胍治疗

疗程为12周。观察两组患者治疗前后空腹血糖（FBG）、餐后2 h血糖（2 h PBG）及糖化血红蛋白（Hb A

c）水平

并以FBG、2 h PBG及Hb A

c水平评估疗效

运用药物经济学原理进行成本-效果分析。结果:治疗12周后

两组患者FBG、2 h PBG及Hb A

c水平均较治疗前明显降低

且米格列醇组患者上述指标水平降低程度较阿卡波糖组更为明显

差异均有统计学意义（P

0.05）。米格列醇组方案上述3项指标疗效的成本-效果比均低于阿卡波糖组

且阿卡波糖组方案相对于米格列醇组的增量成本-效果比分别为26.04、39.06和11.16。米格列醇组、阿卡波糖组患者的不良反应发生率分别为4.0%（2/50）、8.0%（4/50）

差异无统计学意义（P

0.05）。结论:米格列醇能明显降低2型糖尿病患者FBG、2 h PBG和Hb A

c水平

临床疗效显著

不良反应少

具有药物经济学优势。

Abstract

OBJECTIVE:To compare the economical effects of miglitol and acarbose in the treatment of type 2diabetes.METHODS:Totally 100 patients with type 2 diabetes admitted into No.910th Hospital of PLA from Sept.2017 to Aug.2018 were extracted to be divided into the miglitol group and the acarbose group via the admission sequence

with 50 cases in each group.The miglitol group was treated orally with miglitol

while the acarbose group received acarbose.Both groups were additionally given metformin

the course of treatment was 12 weeks.Clinical efficacy such as fasting blood glucose（FBG）

2 h postprandial blood glucose（2 h PBG）

glycated hemoglobin（HbA

c）

the levels of FBG

2 h PBG and HbA

c of two groups were observed before and after treatment

costeffectiveness analysis was performed by using pharmacoeconomics principles.RESULTS:After treatment of 12 weeks

the levels of FBG

2 h PBG and HbA

c in two groups were significantly lower than those before treatment

and the levels of the above indicators in the miglitol group were significantly lower than those in the acarbose group

the differences were statistically significant（P

0.05）.The C/E of the three indicators of the miglitol group were lower than those of the acarbose group

and theΔC/ΔE of the acarbose group to the miglitol group was 26.04

39.06 and11.16

respectively.The incidence of adverse drug reactions in the miglitol group and the acarbose group was 4.0%（2/50）and 8.0%（4/50）

respectively

with no significant difference（P

0.05）.CONCLUSIONS:Miglitol can significantly reduce the levels of FBG

2 h PBG and HbA

c in patients with type 2 diabetes

with significant clinical efficacy

fewer adverse drug reactions and higher advantages of pharmacoeconomics.

关键词

米格列醇阿卡波糖2型糖尿病药物经济学成本-效果

Keywords

MiglitolAcarboseType 2 diabetesPharmacoeconomicsCost-effectiveness

references

查看原文

Views

212

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Pharmacoeconomic Evaluation of Lamotrigine and Sodium Valproate in the Treatment of Epilepsy

Effects of Dapagliflozin Combined with Liraglutide on Inflammatory Factors, Glucolipid Metabolism and Liver Function in Patients with Type 2 Diabetes Combined with Non-Alcoholic Fatty Liver Disease

Clinical Study of Empagliflozin Combined with Insulin Aspart in the Treatment of Patients with Type 2 Diabetes Poorly Controlled by Insulin Alone

Process of Vitamin B₁₂ Deficiency in Patients with Type 2 Diabetes Mellitus Induced by Metformin

Cost-Effectiveness Analysis of Three Kinds of Traditional Chinese Patent Medicines Combined with Methotrexate in the Treatment of Rheumatoid Arthritis

Related Author

HUANG Liyun

LIN Xuejuan

FU Qing

LYU Zhongmei

WANG Deqin

CHU Yang

HUANG Zichong

ZHAO Guishi

Related Institution

Dept. of Neurology,the First Affiliated Hospital of Hainan Medical University

Dept. of Pharmacy,the First Affiliated Hospital of Hainan Medical University

Dept.of Nephroendocrinology, Hai’an Hospital Affiliated to Nantong University

Dept.of Pharmacy,Hospital of China People’s Police University

Dept.of Medicine,Hospital of China People’s Police University

⁰